CAR T-cell perspectives in lupus - Authors' reply
- PMID: 39067897
- DOI: 10.1016/S0140-6736(24)01266-2
CAR T-cell perspectives in lupus - Authors' reply
Conflict of interest statement
GS has received speaker honoraria and consulting fees from Bristol Myers Squibb (BMS), Cabaletta, Janssen, Kyverna, Miltenyi, and Novartis. AM reports grants from Miltenyi Biomedicine and Kyverna; consulting fees from BMS/Celgene, Kite/Gilead, Novartis, BioNTech, Miltenyi Biomedicine, and Century Therapeutics; speaker honoraria from BMS/Celgene, KITE/Gilead, Novartis, and Miltenyi Biomedicine; and support for attending meetings and travel from Abbvie and Janssen. DM has received consulting fees from Galapagos, AvenCell, Incyte, Gilead, and BMS; speaker honoraria from Roche, Miltenyi Biomedicine, AstraZeneca, BMS, and Abbvie; and support for attending meetings and travel from Beigene, Janssen, Roche, BMS, Abbvie, Kyverna, Gilead, Pfizer, and Lilly.
Comment on
-
CAR T-cell perspectives in lupus.Lancet. 2024 Jul 27;404(10450):336. doi: 10.1016/S0140-6736(24)01267-4. Lancet. 2024. PMID: 39067896 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
